BridgeBio Pharma Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2017 | — | $85.9M | $92.0M |
| Mar 2018 | — | $61.7M | — |
| Jun 2018 | — | $204.4M | — |
| Sep 2018 | — | $165.9M | $211.7M |
| Dec 2018 | $54.5M | $314.9M | $436.1M |
| Mar 2019 | — | $252.1M | $373.0M |
| May 2019 | — | $0 | — |
| Jun 2019 | — | $162.9M | $293.8M |
| Sep 2019 | $75.0M | $459.8M | $414.0M |
| Dec 2019 | $91.8M | $408.5M | $363.8M |
| Mar 2020 | $92.4M | $380.7M | $757.0M |
| Jun 2020 | $92.9M | $265.8M | $540.9M |
| Sep 2020 | $93.4M | $163.8M | $367.0M |
| Dec 2020 | $92.4M | $57.9M | $356.1M |
| Mar 2021 | $90.8M | $-395.3M | $471.2M |
| Jun 2021 | $102.6M | $-464.3M | $378.4M |
| Sep 2021 | $103.1M | $-743.4M | $180.3M |
| Dec 2021 | $430.8M | $-870.4M | $393.8M |
| Mar 2022 | $434.1M | $-1.04B | $371.6M |
| Jun 2022 | — | $-1.03B | $470.1M |
| Sep 2022 | — | $-1.14B | $483.2M |
| Dec 2022 | $431.0M | $-1.25B | $376.7M |
| Mar 2023 | $435.8M | $-1.23B | $407.4M |
| Jun 2023 | $440.5M | $-1.36B | $302.4M |
| Sep 2023 | $441.7M | $-1.21B | $505.2M |
| Dec 2023 | $446.4M | $-1.35B | $375.9M |
| Mar 2024 | $434.7M | $-1.05B | $475.2M |
| Jun 2024 | $435.4M | $-1.09B | $408.0M |
| Sep 2024 | $436.2M | $-1.23B | $266.3M |
| Dec 2024 | $437.3M | $-1.47B | $681.1M |
| Mar 2025 | $0 | $-1.65B | $540.6M |
| Jun 2025 | $0 | $-1.79B | $749.0M |
| Sep 2025 | $2.01B | $-1.93B | $643.0M |
| Dec 2025 | $2.01B | $-2.09B | $570.1M |
| Mar 2026 | $2.65B | $-2.28B | $879.9M |
| Jun 2026 | $2.65B | $-2.52B | $677.9M |